Bluestem Capital

What Bluestem Capital does

Bluestem Capital Company, LLC is a Midwest-based private equity firm headquartered at 101 S Phillips Ave, Ste 501 in Sioux Falls, South Dakota, founded in 1989. The firm operates with 1–10 employees — a stable five-partner group led by founding partner Steve Kirby alongside partners Tyler J. Stowater (joined 2000), Sandy Horst (joined 1998, CFO), Nikole Mulder (joined September 2002), and Jon Kirby. Bluestem pursues recapitalizations, buyouts, and mezzanine-style growth equity, targeting growth-stage companies with proven products, market barriers to entry, and management teams with substantial personal financial investment. Its portfolio spans roughly 15 named companies concentrated in healthcare, medical devices, ophthalmology, biotech, real estate, and select consumer/tech — including Sydnexis (pediatric myopia drug SYD-101), Virtual Incision (MIRA miniaturized robotic surgery system), Orasis Pharmaceuticals (Qlosi presbyopia eye drops), Shoulder Innovations (shoulder replacement implants, IPO'd NYSE July 2025), Zerigo Health (NB-UVB phototherapy), Newton (contoured prism lenses), POET (ethanol/biorefining), and Continental Realty Group. The firm deliberately favors face-to-face deal sourcing, "win-win" alignment structures, and co-investment with healthcare-specialist VCs such as RA Capital, Longitude Capital, Visionary Ventures, Arboretum Ventures, and Johnson & Johnson Innovation. Revenue derives from equity returns on portfolio exits — realized through the 2025 Shoulder Innovations IPO, FDA authorizations (MIRA, Feb 2024), EU approval of SYD-101 (June 2025), and ongoing commercialization — rather than disclosed management fees, and the firm operates an AppFolio investor portal for LP reporting.

Name

Bluestem Capital

Legal name

Bluestem Capital Company, LLC

Website

https://bluestemcapital.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

1–10 employees

Short description

Bluestem Capital is a Sioux Falls, South Dakota-based private equity firm founded in 1989 that provides recapitalization, buyout, and growth-equity capital to roughly 15 mid-market companies in healthcare, medtech, ophthalmology, and real estate, favoring hands-on partnerships with aligned management teams.

Ownership category

akta.pro rank

Product category

Private Equity

NAICS

Other Financial Investment Activities (5239)

SIC

Investors, Nec (6799)

akta.pro primary industry

Business Services (B2B) Growth Equity (FSANACAD)

akta.pro secondary industry

SME Term Loans & Growth Capital (FSAKAGAB)

Keywords

• Private equity investment
• Mezzanine financing
• Growth capital
• Recapitalization services
• Buyout financing

Headquarters

HQ city

Sioux Falls

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Private Equity Returns: Bluestem Capital generates returns through equity investments in portfolio companies, expecting financial returns when those companies succeed or exit through acquisition, IPO, or other liquidity events.

Go-to-market motion2 records

Marketing channels4 records

Core offering

Bluestem Capital is a Midwest-based private equity firm that provides growth capital, recapitalization, buyout financing, and mezzanine financing to companies with proven products, strong management teams with substantial financial investment, and market barriers to entry. The firm invests across healthcare, medical technology, biotechnology, real estate, and consumer sectors, focusing on win-win structures that align entrepreneur and investor interests.

Product overview

Bluestem Capital is a Midwest-based private equity firm that invests in portfolio companies across various industries including healthcare, medical technology, biotechnology, real estate, and consumer products. Rather than offering its own unified product platform, Bluestem provides investment and growth capital to companies developing distinct products and services. Key portfolio companies include Zerigo Health (chronic skin condition treatment), Orasis Pharmaceuticals (Qlosi eye drops), Virtual Incision Corporation (MIRA Surgical System), Sydnexis (SYD-101 myopia treatment), Newton (eyecare lenses), Shoulder Innovations (shoulder implants), and others spanning ophthalmology, medtech, biopharmaceuticals, real estate, and nutraceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

• Private Equity Investment (Growth Capital)

Quantifiable outcome

• Successful portfolio company exits and IPOs (e.g., Shoulder Innovations IPO on NYSE July 2025)
• +1 more outcomes

Named customers15 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered core and minor.

• Santen Pharmaceutical Co., Ltd.coreStrategic or Co-development Partner · 5 November 2025Santen licensed rights from Sydnexis to commercialize SYD-101 as Ryjunea in Europe, Middle East, and Africa. Santen is a Japan-based company specialized in eye health operating in 60+ countries.
• HCA Florida Mercy HospitalminorStrategic or Co-development Partner · 22 July 2025First hospital in Southeast U.S. to perform hysterectomy using MIRA Surgical System (Virtual Incision). Part of FDA-approved clinical study under IDE.
• Hoag (Newport Beach, California)minorStrategic or Co-development Partner · 26 February 2025First hospital in Western U.S. to offer MIRA Surgical System through MIRA First Access Program. National leader in robotic-assisted surgery with 30,000+ procedures completed. Designated Center of Excellence in Robotic Surgery (COERS).
• Sovato HealthcoreStrategic or Co-development Partner · 25 November 2024Partner with Virtual Incision for remote robotic-assisted surgery capabilities. Sovato provides the world's only comprehensive solution for enabling remote surgery and procedure programs.
• City of Hope National Medical CenterminorStrategic or Co-development Partner · 25 November 2024Top 5 cancer center (U.S. News & World Report) collaborated on remote robotic surgery demonstration with Virtual Incision and Sovato. Surgeons included Dr. Yuman Fong, Dr. Yanghee Woo, Dr. Yasmin Zerhouni, Dr. Clayton Lau.
• University of Illinois ChicagominorStrategic or Co-development Partner · 25 November 2024Collaborated on remote robotic surgery demonstration with Virtual Incision. Dr. Francesco Maria Bianco performed remote procedures.
• Optus PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 16 October 2024Exclusive licensing agreement with Orasis Pharmaceuticals for commercialization of Qlosi in Korea. $18M in milestone payments plus double-digit royalties.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Sterling Investment Partners: Lower middle-market private equity firm providing growth equity and control capital to consumer, business services, and healthcare companies. Comparable to Bluestem in scale, sector mix, and growth-equity orientation.
• NewSpring Capital: Middle-market private equity firm investing growth equity and controlling stakes across healthcare, tech, and business services. Closely comparable to Bluestem's diversified growth-equity model and stage orientation.
• Linden Capital Partners: Healthcare-focused middle-market private equity firm based in Chicago, investing across healthcare services, medtech, and life sciences. Highly comparable to Bluestem in healthcare sector emphasis and Midwest base.
• Varsity Healthcare Partners: Healthcare-focused lower middle-market private equity firm investing growth capital into healthcare services, devices, and technology companies. Matches Bluestem's healthcare focus and growth-stage orientation.
• GTCR: Chicago-based private equity firm investing in growth-stage companies across healthcare, technology, and business services via minority and control structures. Closely comparable to Bluestem's growth-equity playbook, though at materially larger scale.
• Bison Capital: Lower middle-market private equity firm focused on growth equity investments in founder-led businesses. Directly comparable investment model (minority growth equity, alignment-driven structures) to Bluestem.
• Ampersand Capital Partners: Boston-area private equity firm specializing in healthcare and life sciences growth and buyout investments. Comparable to Bluestem's healthcare portfolio weighting and growth-stage investment orientation.
• Five Points Capital: Lower middle-market private equity firm making control and minority growth investments in healthcare, business services, and specialty industries. Comparable to Bluestem's stage, size, and sector breadth.
• Insight Equity: Middle-market private equity firm focused on control investments and operational improvement across diversified industries. Comparable to Bluestem's lower-middle-market, operationally engaged approach.

Broad incumbents

• Madison Dearborn Partners: Chicago-based private equity firm investing across healthcare, financial services, tech, and consumer via buyouts and growth investments. Compares to Bluestem in geography and sector breadth, but at substantially larger AUM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments29 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bluestem Capital